Austin-based Mirna Therapeutics, Inc. (“Mirna”), a drug development company working on novel therapies for liver cancer and other cancer types, reported yesterday in a press release that the company’s patent claims have been bolstered by the United States Patent and Trademark Office (USPTO), who recently granted “numerous additional composition of matter claims related to the modification of microRNA (miRNA) mimics.” Mirna believes this development will foster more growth and acceleration in their efforts to commercialize its miRNA-based therapeutics. Mirna’s U.S. Patent No. 8,586,727 is rated by PatentBuddy as a strong patent that features expansive international coverage for the company’s patented methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics.
The news of Mirna’s strengthened claims joins previous efforts by the company over the past three years to ensure that its miRNA technologies are properly safeguarded. Earlier patent claims have included the successful registering “composition of matter claims granted to Mirna last year (U.S. Patent No. 8,563,708), which describe multiple chemistries and structures used in therapeutic miRNA mimics, including the one used in MRX34, the Company’s lead clinical candidate” for the treatment of liver and other cancers. Other Mirna patents register the therapeutic use of 15 specific miRNAs for other cancers.
Paul Lammers, President and Chief Executive Officer of Mirna, commented on the growing importance of securing patents for Mirna’s technologies: “Mirna is pleased with the continued expansion of our patent portfolio, and we remain focused on developing innovative miRNA-based therapeutics for cancer patients. This growing intellectual property estate will bring considerable value to our stakeholders, as well as current investors and prospective partners.”
Mirna Recruiting Participants For MRX34 Liver Cancer Therapy Clinical Trial
In addition to the company’s recent patent victories, Mirna also announced that it is still looking for participants for its current Phase 1 clinical trial for MRX34 as a liver cancer therapy. MRX34 is an experimental drug that acts as a miR-34-based therapy and the first miRNA mimic to advance into a human clinical trial. This Phase 1 trial is treating patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
For more information on Mirna’s MRX34 clinical trial for liver cancer, click on the icon below: